Meeting
2023 ASCO Annual Meeting
ProSperA: Phase I study to evaluate safety, tolerability and preliminary efficacy of a bispecific PSMAxCD3 antibody in men with biochemical recurrence of prostate cancer.
Authors
Christopher Hackenbruch
University Hospital Tübingen, German Cancer Consortium (DKTK), Department of Internal Medicine, Clinical Collaboration Unit Translational Immunology, Tübingen, Germany
Christopher Hackenbruch , Jonas S. Heitmann , Juliane S. Walz , Birgit Federmann , Martin Pflügler , Boris A. Hadaschik , Gundram Jung , Helmut R. Salih
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Clinical Trial Registration Number
NCT05646550
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5114)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5114
Abstract #
TPS5114
Poster Bd #
200a
Abstract Disclosures
Similar Posters
First Author: Christopher Hackenbruch
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Susan F. Slovin
Poster
2024 ASCO Genitourinary Cancers Symposium
SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.
First Author: Luke T. Nordquist
Poster
2024 ASCO Genitourinary Cancers Symposium
![Real-life data on [<sup>177</sup>Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in France.](https://d201v5jt9ylckg.cloudfront.net/315/15621/230193/230193_A132_poster_pv.jpg)
Real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in France.
First Author: Guilhem Roubaud